A Phase 2 interventional study of Cetuximab and Bevacizumab in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-07.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2006, is one of 31 in phase 2, and was the 24th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Jonathan Riess · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 38 · Phase 3 6
First in 2000; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 63 across the 51 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 52 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 62nd largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 38th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycles 1-6: * Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week * Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle * Paclitaxel 200 mg/m² on day 1 of every 3 week cycle * Carboplatin area under curve (AUC=6 min\*mg/mL) on day 1 of every 3 week cycle Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Biological: Cetuximab · Biological: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin
Cycles 1-6: * Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week * Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle Cycles 1-3: * Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles * Carboplatin AUC=6 min\*mg/mL on day 1 of each 3 week cycle for the first 3 cycles Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Biological: Cetuximab · Biological: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin
Administered intravenously
Also known as: Erbitux
Administered intravenously
Administered intravenously
Administered intravenously
Progression Free Survival (PFS)
PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.
Time frame: Randomization to PD or date of death from any cause up to 33.1 months
Overall Survival
Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.
Time frame: Randomization to the date of death from any cause up to 42.7 months
Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate)
The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.
Time frame: Randomization to measured progressive disease up to 31.8 months
Duration of Overall Response
The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.
Time frame: Time of first response to the first date of PD or death due to any cause up to 31.8 months
Percentage of Participants With Symptomatic Response (Symptom Response Rate)
Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.
Time frame: From date of partial response until progression of disease up to 31.8 months
| Milestone | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Started | 60 | 61 |
| Received at least one dose of study drug | 58 | 58 |
| Completed | 3 | 5 |
| Not completed | 57 | 56 |
| Withdrew: Adverse event | 13 | 13 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Progressive disease | 33 | 34 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 8 | 5 |
PFS is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD ≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.
| months | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Progression Free Survival (PFS) | 6.05 (5.65 to 7.03) | 4.50 (4.01 to 5.42) |
Overall survival is defined as the time from randomization to death. Participants who are alive will be censored on the last known alive date.
| months | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Overall Survival | 12.06 (9.40 to 19.25) | 11.63 (6.64 to 17.61) |
The best objective overall response rate (ORR) is the percentage of randomized participants with a best overall response of complete response (CR) or partial response (PR), as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions. ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated in that arm, multiplied by 100. Participants with no post-baseline evaluation will be considered as a non-responder.
| percentage of participants | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate) | 51.7 (39.0 to 64.3) | 44.3 (31.8 to 56.7) |
The duration of response, in participants with best overall response of CR or PR, is measured from the date criteria are met for CR/PR (whichever is first recorded), until the first date that the criteria for PD is met or death. CR, PR, and PD, as classified by the investigator according to the RECIST guidelines. CR=disappearance of all target lesions; PR≥30% decrease in sum of longest diameter of target lesions; PD≥20% increase in sum of longest diameter of target lesions. Participants who are alive and without PD will be censored at the date of their last tumor assessment.
| months | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Duration of Overall Response | 4.86 (4.30 to 7.16) | 3.94 (2.92 to 4.47) |
Functional Assessment of Cancer Therapy for Patients With Lung Cancer (FACT-L) measures domains of health-related quality of life (HR-QL): physical wellbeing (WB), social/family WB, emotional WB, functional WB, and additional lung cancer concerns. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item Lung cancer subscale (LCS) score maintained for 2 consecutive assessments. Scores range from 0-28 with higher scores indicating fewer symptoms. Patients with a score of \>26 were not evaluable for symptom response, since a score of 28 is the maximum possible.
| percentage of participants | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Percentage of Participants With Symptomatic Response (Symptom Response Rate) | 41.9 (27.1 to 56.6) | 38.6 (24.2 to 53.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | — | 38/58 (65.5%) | 56/58 (96.6%) |
| Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | — | 28/58 (48.3%) | 57/58 (98.3%) |
| Event | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| PneumoniaInfections and infestations | 4/58 | 5/58 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/58 | 5/58 |
| VomitingGastrointestinal disorders | 4/58 | 2/58 |
| Disease progressionGeneral disorders | 4/58 | 3/58 |
| DehydrationMetabolism and nutrition disorders | 4/58 | 2/58 |
| ConstipationGastrointestinal disorders | 3/58 | 0/58 |
| NauseaGastrointestinal disorders | 3/58 | 1/58 |
| PyrexiaGeneral disorders | 3/58 | 0/58 |
| HypersensitivityImmune system disorders | 1/58 | 3/58 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/58 | 1/58 |
| Event | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) |
|---|---|---|
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 45/58 | 40/58 |
| FatigueGeneral disorders | 32/58 | 28/58 |
| NauseaGastrointestinal disorders | 30/58 | 23/58 |
| StomatitisGastrointestinal disorders | 19/58 | 23/58 |
| ConstipationGastrointestinal disorders | 22/58 | 16/58 |
| DiarrhoeaGastrointestinal disorders | 22/58 | 14/58 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/58 | 22/58 |
| AnaemiaBlood and lymphatic system disorders | 21/58 | 10/58 |
| HypomagnesaemiaMetabolism and nutrition disorders | 19/58 | 13/58 |
| Decreased appetiteMetabolism and nutrition disorders | 17/58 | 18/58 |
| Age Continuous(years) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| Mean | 63.4 ± 11.52 | 62.1 ± 8.97 | 62.8 ± 10.29 |
| Age, Customized(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| < 65 years | 31 | 32 | 63 |
| ≥ 65 years | 29 | 29 | 58 |
| Age, Customized(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| < 70 years | 41 | 51 | 92 |
| ≥ 70 years | 19 | 10 | 29 |
| Sex: Female, Male(Participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| Female | 25 | 27 | 52 |
| Male | 35 | 34 | 69 |
| Race/Ethnicity, Customized(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| White | 53 | 53 | 106 |
| Black | 2 | 4 | 6 |
| Asian | 1 | 2 | 3 |
| Hispanic | 3 | 0 | 3 |
| Other | 1 | 2 | 3 |
| Region of Enrollment(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| United States | 60 | 61 | 121 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| 0 - Full Active | 24 | 29 | 53 |
| 1 - Ambulatory, Restricted Strenuous Activity | 28 | 27 | 55 |
| Missing/Unknown | 8 | 5 | 13 |
| Smoking Status(participants) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6) | Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3) | Total |
|---|---|---|---|
| Current | 17 | 11 | 28 |
| Past | 37 | 44 | 81 |
| Exposed to Second-hand Smoke | 2 | 1 | 3 |
| Not Exposed to Second-hand Smoke | 4 | 4 | 8 |
| Missing/Unknown | 0 | 1 | 1 |
The record gives a start of Dec 2006, a primary completion of May 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Bevacizumab · Paclitaxel · Carboplatin
Carcinoma, Non-Small-Cell Lung →